A patient walks into your clinic with a delayed nodule. Would you know what to do next?
With emerging reports involving semaglutide and tirzepatide, should GLP-1 treatment now form part of your complication assessment?
Delayed-onset nodules (DONs) are not a single diagnosis. A lump appearing weeks or months after filler may represent a non-inflammatory product-related nodule, a sterile inflammatory response, a granulomatous reaction, infection, a biofilm-associated process, or an abscess. The distinction matters because these presentations should not all be managed in the same way.
The GLP-1 story adds a new and clinically interesting layer. Recent reports have described delayed reactions at previous aesthetic injection sites in patients using semaglutide or compounded tirzepatide. These reports do not establish that GLP-1 or related incretin medicines cause filler nodules. They do, however, raise a question practitioners may increasingly need to consider when taking a complication history.
Why Two Face Aesthetics is writing about this
At Two Face Aesthetics, we have managed patients presenting with significant delayed filler complications where GLP-1/GIP treatment formed part of the clinical history, including clinically significant inflammatory or suspected infective presentations.
Our experience cannot establish that GLP-1 therapy caused these complications. It has, however, made us particularly interested in the emerging literature and in whether GLP-1/GIP medication should routinely be considered when taking the history of a patient presenting with a delayed filler complication.
That distinction is essential. Clinical observation can identify a pattern worth investigating; it cannot establish incidence, quantify risk, or prove causation.
What are delayed-onset filler nodules?
DONs are lumps, areas of firmness, swelling, or inflammatory lesions arising after the expected immediate recovery period following an injectable treatment. They can appear weeks or months later, sometimes after the treated area has appeared completely settled.
Consensus literature emphasizes that late-onset reactions after hyaluronic acid filler are heterogeneous. Potential contributors include filler characteristics, host inflammatory responses, immune-triggering events, and infection. A delayed nodule should therefore be treated as a clinical presentation requiring assessment rather than as a diagnosis in itself.
Why are GLP-1 medications now part of the discussion?
In March 2026, Moore, Hurley and Moore reported a 66-year-old patient who developed persistent facial nodules at previous hyaluronic acid filler, calcium hydroxylapatite filler, and incobotulinumtoxinA injection sites after beginning compounded tirzepatide. The patient had previously tolerated similar aesthetic treatments. The report described cessation of new nodules after compounded tirzepatide was stopped and later recurrence following rechallenge and dose escalation.
That temporal pattern is noteworthy, but it is not proof of causation. The authors identified important limitations, including the use of a compounded tirzepatide product with incompletely characterized ingredients, lack of biopsy, and the inability to definitively exclude infection.
Subsequent 2026 correspondence in JAAD Case Reports has continued the discussion around inflammation-mediated facial nodules associated with compounded tirzepatide. Published commentary has also challenged a purely inflammatory interpretation and highlighted the importance of adequately considering infectious and biofilm-related complications.
That debate is clinically valuable. The key question is not simply, “Could GLP-1 treatment trigger inflammation?” It is also: what if the nodule is not simply a sterile inflammatory reaction?
Separate dermatology literature has also described a reported delayed facial edema/inflammatory reaction involving previously placed hyaluronic acid filler following semaglutide initiation. This does not establish a class effect, but it adds to the rationale for documenting incretin-based medication when assessing delayed reactions.
Tirzepatide is a dual GIP/GLP-1 receptor agonist rather than a pure GLP-1 receptor agonist. We use “GLP-1 medication” here in the common clinical shorthand while distinguishing the pharmacology where relevant.
A delayed nodule is a differential diagnosis, not a treatment recipe
When a patient presents with a delayed lump, practitioners should consider several possibilities rather than assuming every DON has the same cause:
- Non-inflammatory/product-related nodule: product placement, accumulation, migration, or other local filler-related factors may be relevant.
- Sterile inflammatory reaction: tenderness, edema, erythema, or recurrent swelling may reflect an inflammatory response without established infection.
- Granulomatous response: a chronic inflammatory tissue response requires appropriate clinical assessment and may need specialist input.
- Infection or biofilm-associated process: particularly important where pain, erythema, warmth, fluctuance, drainage, or progressive symptoms are present.
- Abscess: a collection requires a different diagnostic and management pathway from a simple non-inflammatory nodule.
The terminology matters because suppressing inflammation without adequately considering infection can be inappropriate, while treating every nodule as infection is equally simplistic.
A patient presents with a delayed nodule — what should you do?
1. Establish the timeline
Build the chronology before deciding what the lesion represents. Record the filler date, product, treatment location, injector if known, and when symptoms began. Ask specifically about GLP-1/GIP medication initiation, recent dose escalation or medication changes. Also document recent illness or infection, dental treatment, vaccination, and other medicines.
2. Examine the presentation
Determine whether the lesion appears inflammatory or non-inflammatory. Assess tenderness, erythema, warmth, induration, fluctuance, drainage, distribution across one or multiple injection sites, progression, and any systemic symptoms.
A painful, warm, erythematous, or fluctuant lesion should raise concern for infection or abscess and warrants appropriate medical assessment.
3. Know what was injected
The material matters. Hyaluronic acid filler can potentially be degraded with hyaluronidase in appropriate circumstances. Calcium hydroxylapatite, poly-L-lactic acid, and other non-HA products require different thinking and cannot simply be “dissolved” with hyaluronidase.
Where the product is unknown, obtain treatment records if possible rather than guessing.
4. Consider infection before suppressing inflammation
This is one of the most important decision points. A delayed inflammatory-looking lesion is not automatically a sterile inflammatory reaction. Infection, abscess, and biofilm-associated processes belong in the differential diagnosis, particularly when clinical signs support them.
The 2026 debate around the compounded tirzepatide case reinforces this point: an apparent temporal medication association does not remove the need to investigate alternative explanations.
5. Investigate where appropriate
Ultrasound can be extremely useful in experienced hands for identifying filler location, characterizing nodules, distinguishing diffuse tissue change from a collection, and guiding further management. Where infection or abscess is suspected, microbiological investigation, drainage, imaging, or other medical assessment may be appropriate depending on the presentation.
6. Do not reflexively treat every DON identically
There is no single universal “delayed nodule treatment.” Management should follow the working diagnosis, injected material, severity, and clinical findings. Hyaluronidase may be relevant to selected HA filler complications, but it is not a universal answer. Likewise, antibiotics, corticosteroids, or other prescription treatments should not be used as a generic recipe without appropriate assessment.
7. Know when to escalate or refer
Escalate when the diagnosis is uncertain, symptoms are significant or progressive, infection or abscess is suspected, the patient is systemically unwell, the injected product is unknown, initial management has failed, or the presentation falls outside the practitioner's competence.
Patients with severe or rapidly worsening symptoms, significant spreading redness or swelling, systemic illness, or other features suggesting a serious infection should receive urgent medical assessment.
Should GLP-1/GIP treatment now be part of the complication history?
We believe it is reasonable to ask about it. That does not mean attributing the complication to the medication.
When assessing a DON, document semaglutide, tirzepatide, or other incretin-based treatment; when it began; recent dose changes; and its temporal relationship to symptoms. This information may become increasingly valuable as the evidence base develops.
Patients should not stop or alter prescribed semaglutide, tirzepatide, or another medication solely because of an article or a suspected filler reaction. Medication decisions should be discussed with the clinician responsible for prescribing and monitoring treatment, alongside the clinician assessing the aesthetic complication.
What does the evidence actually allow us to say?
It does not currently allow us to say that GLP-1 medications cause delayed filler nodules.
Case reports and correspondence are useful for identifying possible safety signals, but they cannot determine incidence or establish cause and effect. The compounded nature of the tirzepatide exposure in the principal 2026 case is an especially important limitation when considering whether the observation can be generalized to approved tirzepatide products.
Millions of patients use incretin-based therapies, and many have a history of aesthetic injectable treatment. Coincidental delayed reactions will therefore occur. Larger datasets and better-characterized cases are needed to determine whether there is a genuine additional risk, which patients may be susceptible, and whether medication initiation or dose escalation is relevant.
The practical takeaway for aesthetic practitioners
GLP-1/GIP medication should not become a shortcut diagnosis for every delayed filler complication. The more useful lesson is the opposite: take a broader history and perform a more disciplined differential assessment.
If an unusual delayed reaction occurs, document the filler, timing, medication history, dose changes, immune triggers, clinical signs, investigations, and outcome. That is how isolated observations eventually become useful evidence.
For Two Face Aesthetics, our own clinical experience is why we are following this subject closely. The emerging GLP-1 literature is genuinely interesting, but the priority when a patient presents remains identifying what the nodule actually represents and managing or referring it appropriately.
References and further reading
- Moore L, Hurley K, Moore A. Facial nodules following filler injections after initiating compounded tirzepatide use. JAAD Case Reports. 2026. doi:10.1016/j.jdcr.2026.03.042. PMID: 42088720. PubMed.
- Inflammation-mediated facial nodules to compounded tirzepatide. JAAD Case Reports. 2026. Subsequent correspondence discussing the reported presentation and possible inflammatory mechanisms.
- Benefit-Risk Assessment of GLP-1 Receptor Agonists: Implications for Dermatologists and Plastic Surgeons. Dermatology and Therapy. 2025. Review discussing dermatologic and aesthetic implications of GLP-1 receptor agonists, including a reported delayed inflammatory reaction involving previous HA filler after semaglutide initiation.
- Late-Onset Reactions after Hyaluronic Acid Dermal Fillers: A Consensus Recommendation on Etiology, Prevention and Management. 2024. PMID: 38907876. PubMed.
- Artzi O, et al. Delayed Inflammatory Reactions to Hyaluronic Acid Fillers: A Literature Review and Proposed Treatment Algorithm. PubMed Central.
- U.S. Food and Drug Administration. Dermal Fillers (Soft Tissue Fillers). FDA.
This article is intended for general professional education. It does not establish that GLP-1/GIP medications cause delayed filler reactions and is not a substitute for individualized medical assessment, diagnosis, or treatment. Practitioners should work within their training, scope, and applicable local requirements and refer or escalate complications where appropriate.
Related professional product ranges
For professional product information and current availability, browse our dermal filler collection, Sculptra, Restylane, JUVÉDERM and Radiesse.
